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Hemophilia A (HA) and B (HB) are estimated to affect 1 in 5,000 male births in the United 
States each year.[1] Inheritance of mutations in the Factor VIII (F8) gene or Factor IX (F9) 
gene causes these bleeding disorders. Identification of mutations causing a patient’s 
hemophilia can lead to better understanding of risk of complications [2], as well as aid in 
carrier detection in family members [3]. Mutation screening for HA has involved testing for 
inversions of introns 1 and 22 of F8, as approximately 45% of severe HA patients carry an 
inversion as their causative mutation [2], and sequencing of the coding regions of F8 to 
identify point mutations, deletions, or splice-site mutations. Similarly, mutation screening 
for HB has involved sequencing of the coding regions of F9. However, a subset of patients 
presenting with hemophilia do not to have a detectable mutation with these methods.[4] 
Duplication of part of F8 or F9, for example, may not be detected. Also, female family 
members heterozygous for a large F8 or F9 deletion may not be identified as carriers using 
these methods, as dosage of the genes is not determined. Recently, Multiplex Ligation-
Dependent Probe Amplification (MLPA®, MRC Holland, Amsterdam, Netherlands) has 
been successfully used to identify large deletions and duplications within F8 and F9.[5-7] 
This assay quantitatively compares copy numbers of a set of DNA sequences in a patient 
sample to those in a control sample to screen for the presence of deletions or duplications.[8] 
The assessment of how this or similar technologies will fit into currently-used mutation 
screening protocols should be critically evaluated.
We describe here our experience using MLPA® in combination with inversion testing and 
DNA sequencing for identification of mutations in a large series of hemophilia patients. 
Additionally, we present our analyses of how this duplication/deletion testing fits into 
mutation screening algorithms and highlight the importance of careful assay validation and 
interpretation.
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A subset of patients enrolled in the Hemophilia Inhibitor Research Study were studied for 
this report.[2] At the time of this study, mutation analysis had been completed on 930 HA 
patients enrolled in the Hemophilia Inhibitor Research Study (250 more patients than in the 
previous report) and 152 HB patients. Patients with no mutation detected by inversion 
testing or sequencing and patients with large deletions detected by sequencing were 
screened with MLPA® SALSA Kits P178 for F8 and P207 for F9 (MRC Holland, 
Amsterdam, The Netherlands) following the manufacturer’s protocol. MLPA® fragments 
were separated and sized using the 3730 DNA Analyzer (Applied Biosystems, Carlsbad, 
California, USA) and analyzed using the GeneMapper® 4.0 (Applied Biosystems) and 
Coffalyzer® (MRC Holland) software packages. Large duplications were confirmed with 
TaqMan® CNV assays (Applied Biosystems) custom-designed to assay the region of the 
duplication following the manufacturer’s protocol.
Of the 930 HA patients included in the study, 47 (5%) patients who did not have a mutation 
detected by inversion testing or F8 sequencing and 28 (3%) HA patients with large deletions 
within F8 were screened. Large duplications were identified in 8 (17%) patients with no 
mutation previously detected and were confirmed with TaqMan® CNV assays. All large 
deletions initially identified by sequencing were confirmed by MLPA®. Figure 1A outlines 
the algorithm used to identify mutations in this patient population. MLPA® allowed the 
identification of 8 more mutations in this population, resulting in 96% of patients having an 
identified mutation.
Of the 152 HB patients included in the study, 2 (1%) patients with no mutation detected by 
F9 sequencing and 6 (4%) patients with large deletions were screened with MLPA®. No 
large duplications were identified. All large deletions were confirmed by MLPA®. Figure 
1B outlines the algorithm used to identify mutations in this patient population. MLPA® did 
not allow the identification of any more mutations in this population. However, it did allow 
the confirmation of all of the large deletions detected by sequencing.
In the Hemophilia Inhibitor Research Study 5% of severe HA patients and 13% of severe 
HB patients carry a large deletion or duplication.[2] Similar distributions have been seen in 
other population-based studies.[9-11] Inhibitors are estimated to occur in approximately 
50% of HA and HB patients with large deletions or duplications.[2, 12] Our experience 
screening F8 and F9 with MLPA® resulted in the successful confirmation of all 28 deletions 
in F8 and all 6 deletions in F9 identified by DNA sequencing. Furthermore, 8 duplications 
were identified in 47 HA patients with no previous mutation identified.
In order to most efficiently identify mutations and classify those at-risk for developing 
inhibitors as this technology enters the clinical setting, we propose the screening algorithms 
outlined in Figure 1. Because approximately 40% of HA patients carry an inversion and 
because inversion carriers are at moderate risk for inhibitor development [12], we propose 
initially screening for F8 inversions in patients with HA. If no inversion is identified, F8 
sequencing would be subsequently conducted. It is estimated this would identify over 95% 
of mutations leading to HA.[2, 4] If no mutation is identified through sequencing, MLPA® 
should then be conducted to identify possible large duplications. Similarly, we propose 
initially sequencing F9, followed by MLPA® if no mutation is identified.
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In carrier screening for either HA or HB, the algorithm would be altered depending on the 
mutation identified in the index case. For example, if a point mutation or small insertion/
deletion were identified in the index case, only the amplicon for the gene region surrounding 
the mutation would need to be sequenced to determine carrier status. Because large deletions 
and duplications in carriers would result in an altered copy number in the region of the 
deletion or duplication, we propose using MLPA® to identify carriers of these mutations, as 
sequencing would not be able to detect these copy number changes.
The proper use of MLPA® or similar technologies to screen for genomic deletions or 
duplications in hemophilia requires careful attention to several key aspects: choice of control 
samples; interpretation of results; and choice of DNA extraction methods. Because F8 and 
F9 are X-linked genes, it is necessary that reference samples be obtained from subjects of 
the same sex as the tested patient in order to correctly measure the ratio of copy numbers in 
the samples. It is also important to consider the assay-specific control probe composition 
when using male reference samples to assay female carriers or, alternatively, using female 
reference samples to assay male patients. For example, the F8 MLPA® control probe 
sequences are in X-linked genomic regions, while those in the F9 kit are autosomal. Also, 
the assay is sensitive to sample impurities and inconsistencies may be introduced by using 
multiple DNA extraction methods. Finally, due to the complicated nature of quantitative 
assays to determine copy number variation, assay validation is essential. Initial results must 
be confirmed by repeated testing with an independent method, such as quantitative PCR.
MLPA® kits surveying the F8 and F9 gene are useful for identifying deletions and 
duplications causing HA and HB. The kits help to identify previously-undetectable 
mutations and provide a method for rapid identification of patients most at-risk for 
complications of inhibitors. However, appropriate caution must be taken to validate results 
and ensure correct interpretation.
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Fig 1. 
Mutation screening algorithms incorporating MLPA® a: Mutation screening algorithm for 
HA patients enrolled in the Hemophilia Inhibitor Research Study b: Mutation screening 
algorithm for HB patients enrolled in the Hemophilia Inhibitor Research Study
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